Literature DB >> 2369570

Renal side-effects of cyclosporin A.

J Mason1.   

Abstract

Cyclosporin A (CyA) has multiple effects on the kidney. The drug can cause changes in either the tubular or vascular system which may be either functional or structural, reversible or irreversible and frequent or seldom. Functional changes to the tubules and vessels are common, occur at low doses and are reversible, while structural changes to the tubules and vessels are rare, occur at high doses and are not always reversible. The changes of importance are vascular. By harnessing two strategies to restrain the development of side-effects--limiting the dose and restricting the functional changes--it is possible to avoid irreversible damage to the kidney in patients treated with CyA.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2369570     DOI: 10.1111/j.1365-2133.1990.tb02884.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

1.  Acute tubular necrosis following high-dose cyclosporine A therapy.

Authors:  P Shechter
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 2.  Cyclosporin: a pharmacoeconomic evaluation of its use in renal transplantation.

Authors:  J E Frampton; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

3.  Engineering polysaccharide-based polymeric micelles to enhance permeability of cyclosporin A across Caco-2 cells.

Authors:  Mira F Francis; Mariana Cristea; Yali Yang; Françoise M Winnik
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

4.  Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Masuho Saburi; Sumiko Kohashi; Jun Kato; Yuya Koda; Masatoshi Sakurai; Takaaki Toyama; Taku Kikuchi; Daiki Karigane; Sayako Yuda; Yusuke Yamane; Risa Hashida; Ryohei Abe; Tomonori Nakazato; Junichi Hirahashi; Masao Ogata; Shinichiro Okamoto; Takehiko Mori
Journal:  Int J Hematol       Date:  2017-05-17       Impact factor: 2.490

Review 5.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 6.  Cyclosporin clinical pharmacokinetics.

Authors:  A Fahr
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

7.  Cyclosporin A Prevents Ovarian Graft Rejection, and Permits Normal Germ Cell Maturation Within the First 5 Weeks Post-transplantation, in the Domestic Turkey (Meleagris gallopavo).

Authors:  George B Hall; Janet Beeler-Marfisi; Julie A Long; Benjamin J Wood; Gregoy Y Bedecarrats
Journal:  Front Vet Sci       Date:  2022-04-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.